212 related articles for article (PubMed ID: 10943907)
1. Pharmacological validation of a new animal model of alcoholism.
Spanagel R; Hölter SM
J Neural Transm (Vienna); 2000; 107(6):669-80. PubMed ID: 10943907
[TBL] [Abstract][Full Text] [Related]
2. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
Spanagel R; Zieglgänsberger W
Trends Pharmacol Sci; 1997 Feb; 18(2):54-9. PubMed ID: 9090311
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.
Littleton J; Zieglgänsberger W
Am J Addict; 2003; 12(s1):s3-s11. PubMed ID: 14972776
[TBL] [Abstract][Full Text] [Related]
4. Effect of the combination of naltrexone and acamprosate on alcohol intake in mice.
Kim SG; Han BD; Park JM; Kim MJ; Stromberg MF
Psychiatry Clin Neurosci; 2004 Feb; 58(1):30-6. PubMed ID: 14678454
[TBL] [Abstract][Full Text] [Related]
5. The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.
Ooteman W; Koeter MW; Verheul R; Schippers GM; van den Brink W
Eur Neuropsychopharmacol; 2007 Jul; 17(8):558-66. PubMed ID: 17379484
[TBL] [Abstract][Full Text] [Related]
6. Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?
Kiefer F; Jahn H; Otte C; Naber D; Wiedemann K
Biol Psychiatry; 2006 Jul; 60(1):74-6. PubMed ID: 16483549
[TBL] [Abstract][Full Text] [Related]
7. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
Kiefer F; Jahn H; Otte C; Demiralay C; Wolf K; Wiedemann K
J Psychiatr Res; 2005 Sep; 39(5):545-51. PubMed ID: 15992564
[TBL] [Abstract][Full Text] [Related]
8. Anti-craving drugs acamprosate and naloxone do not reduce expression of morphine conditioned place preference in isolated and group-housed rats.
Herzig V; Schmidt WJ
Neurosci Lett; 2005 Feb; 374(2):119-23. PubMed ID: 15644276
[TBL] [Abstract][Full Text] [Related]
9. Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze.
Cole JC; Littleton JM; Little HJ
Psychopharmacology (Berl); 2000 Jan; 147(4):403-11. PubMed ID: 10672634
[TBL] [Abstract][Full Text] [Related]
10. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats.
Heyser CJ; Schulteis G; Durbin P; Koob GF
Neuropsychopharmacology; 1998 Feb; 18(2):125-33. PubMed ID: 9430136
[TBL] [Abstract][Full Text] [Related]
11. The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats.
Kratzer U; Schmidt WJ
Neurosci Lett; 1998 Aug; 252(1):53-6. PubMed ID: 9756357
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapies for alcoholism: the old and the new.
Olive MF
CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):2-4. PubMed ID: 20232494
[TBL] [Abstract][Full Text] [Related]
13. Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats.
Czachowski CL; Delory MJ
Psychopharmacology (Berl); 2009 Jun; 204(2):335-48. PubMed ID: 19153715
[TBL] [Abstract][Full Text] [Related]
14. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Rösner S; Leucht S; Lehert P; Soyka M
J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
[TBL] [Abstract][Full Text] [Related]
15. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
[TBL] [Abstract][Full Text] [Related]
16. Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone.
Escher T; Mittleman G
Addict Biol; 2006 Mar; 11(1):55-63. PubMed ID: 16759337
[TBL] [Abstract][Full Text] [Related]
17. Drugs for relapse prevention of alcoholism: ten years of progress.
Spanagel R; Kiefer F
Trends Pharmacol Sci; 2008 Mar; 29(3):109-15. PubMed ID: 18262663
[TBL] [Abstract][Full Text] [Related]
18. Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.
Liang J; Olsen RW
Acta Pharmacol Sin; 2014 Aug; 35(8):981-93. PubMed ID: 25066321
[TBL] [Abstract][Full Text] [Related]
19. Animal models of craving for ethanol.
Koob GF
Addiction; 2000 Aug; 95 Suppl 2():S73-81. PubMed ID: 11002904
[TBL] [Abstract][Full Text] [Related]
20. Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats.
Vengeliene V; Leonardi-Essmann F; Sommer WH; Marston HM; Spanagel R
Biol Psychiatry; 2010 Oct; 68(8):704-11. PubMed ID: 20655511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
